Gatot Soegiarto, - and Jonny Karunia Fajar, - and Laksmi Wulandari, - and Muhammad Anshory, - and Muhammad Ilmawan, - and Anisa Asmiragani, - and Himma illiyana, - and Azaria Adam, - and Sutini Lamadi, - and Umi Sa'adah, - and Tubagus Yuantoko, - and Esi Nanda, - and Farida Rachmawati, - and Nabila Rahmadani, - and Randy Talilah, - and Madyline Katipana, - and Sharon Susanto, - and Maria Hindom, - and Ufi Anjasari, - and Nur Hidayah, - and Nanda Fadilla, - and Vanela Lekatompessy, - and Uzi Phoenna, - and Fredo Tamara, - and Dessy Aprilia Kartini, - and Aditya Indra Mahendra, - and Andi Permana, - and Erwin Alexander Pasaribu, - and Kuldeep Dhama, - and Harapan, - (2022) Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials [version 1; peer review: 1 approved with reservations]. F1000Research, 11 (299). pp. 1-19. ISSN 2046-1402

	Text (Artikel) Artikel 1.pdf Download (1MB)
	Text (Peer Review) Karil Artikel 1.pdf Download (658kB)
	Text (Bukti Korespondensi) korespondensi sero.pdf Download (1MB)
	Text (Similarity) Turnitin Artikel 1.pdf Download (3MB)

Abstract

BACKGROUND: The COVID-19 vaccination program, which uses various types of vaccines, has been applied since the beginning of 2021. However, the efficacy in the context of seroconversion rate remains unclear. OBJECTIVE: To assess the seroconversion rates among different COVID-19 vaccines using a network meta-analysis approach. METHODS: A network meta-analysis of randomized controlled trials (RCTs) was conducted during the study period. Data of interest, such as seroconversion rate and the type of COVID-19 vaccine, were extracted from each study. The analysis was performed using single-arm analysis by calculating the cumulative seroconversion rate. A network meta-analysis was conducted using the Bayesian method. RESULTS: A total of 31 RCTs were included in our analysis. Our pooled calculation revealed that the seroconversion rates of inactivated messenger ribonucleic acid (mRNA), protein subunit, and vector COVID-19 vaccines during the follow-up periods were 93.2%, 93.9%, 65.3%, and 54.7%, respectively, at ≤ 15 days; 96.0%, 94.8%, 91.2%, and 89.7%, respectively, between days 16–30; and 98.5%, 98.6%, 98.5%, and 96.2%, respectively, between days 31–60.The indirect comparison revealed that in the follow-up periods of ≤ 15 and 16–30 days, the inactivated and mRNA COVID-19 vaccines had superior seroconversion rates compared with those of the protein subunit and vector vaccines. In the follow-up period of 31–60 days, the highest seroconversion rates were found in the inactivated, mRNA, and protein subunit COVID-19 vaccines. CONCLUSION: This study provides valuable information regarding the comparison of seroconversion rates of COVID-19 vaccines.

Actions (login required)

View Item